Research programme: pain therapeutics - AurimMed Pharma
Latest Information Update: 10 Jan 2024
At a glance
- Originator AurimMed Pharma
- Class Analgesics; Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammatory pain; Pain
Most Recent Events
- 10 Jan 2024 The research programme is still in preclinical development for Inflammatory-pain in USA (AurimMed Pharma, pipeline 2024)
- 10 Jan 2024 The research programme is still in preclinical development for Pain in USA (AurimMed Pharma, pipeline 2024)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Inflammatory-pain in USA